Cash Equivalents - C4 Therapeutics Inc (NASDAQ:CCCC) - Alpha Spread

Watchlist Manager

Watchlist

Price: 5.68 USD -4.86%

Updated:

C4 Therapeutics Inc
Cash Equivalents

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

|

Adjust for Inflation

C4 Therapeutics Inc
Cash Equivalents Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
	C4 Therapeutics Inc NASDAQ:CCCC	Cash Equivalents $126.6m	CAGR 3-Years -11%	CAGR 5-Years 28%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Cash Equivalents $18.1B	CAGR 3-Years 23%	CAGR 5-Years 30%	CAGR 10-Years 8%
	Gilead Sciences Inc NASDAQ:GILD	Cash Equivalents $4.7B	CAGR 3-Years 5%	CAGR 5-Years -23%	CAGR 10-Years -3%
	Amgen Inc NASDAQ:AMGN	Cash Equivalents $9.7B	CAGR 3-Years 17%	CAGR 5-Years 6%	CAGR 10-Years 10%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Cash Equivalents $9.2B	CAGR 3-Years 13%	CAGR 5-Years 26%	CAGR 10-Years 36%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Cash Equivalents $2.6B	CAGR 3-Years 22%	CAGR 5-Years 9%	CAGR 10-Years 19%

See Also

Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Cash Equivalents amounts to 126.6m USD.

Over the last year, the Cash Equivalents growth was 325%. The average annual Cash Equivalents growth rates for C4 Therapeutics Inc have been -11% over the past three years , 28% over the past five years .

Join more than 138,400+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.